Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

ErbB family targeting.

Jennifer D Black¹, Michael G Brattain, Smitha A Krishnamurthi

¹Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Current Opinion in Investigational Drugs (London, England : 2000)

|February 7, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells.

The Journal of clinical investigation·2025

Same author

Inhibition of <i>O</i>-GlcNAc transferase activates type I interferon-dependent antitumor immunity by bridging cGAS-STING pathway.

eLife·2024

Same author

Cbl and Cbl-b ubiquitin ligases are essential for intestinal epithelial stem cell maintenance.

iScience·2024

Same author

Inhibition of <i>O</i>-GlcNAc transferase activates type I interferon-dependent antitumor immunity by bridging cGAS-STING pathway.

bioRxiv : the preprint server for biology·2024

Same author

Cbl and Cbl-b Ubiquitin Ligases are Essential for Intestinal Epithelial Stem Cell Maintenance.

bioRxiv : the preprint server for biology·2023

Same author

Crosstalk between protein kinase C α and transforming growth factor β signaling mediated by Runx2 in intestinal epithelial cells.

The Journal of biological chemistry·2023

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Targeted cancer therapies show promise, but epidermal growth factor receptor antagonists are not effective alone. This review explores challenges and solutions for optimizing their use in cancer treatment.

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Recent advances in molecular understanding of cancer have spurred development of targeted therapies.
Antibodies and small molecule kinase inhibitors have demonstrated clinical utility in cancer treatment.
The ErbB receptor family is a key focus for targeted cancer therapies currently in clinical trials.

Purpose of the Study:

To discuss the challenges in optimizing the clinical application of epidermal growth factor receptor antagonists.
To review current approaches aimed at resolving these challenges in cancer therapy.

Main Methods:

Literature review of targeted cancer therapies.
Analysis of clinical trial data for ErbB-targeted agents.
Discussion of strategies for improving efficacy of molecularly targeted drugs.

Related Experiment Videos

Main Results:

Epidermal growth factor receptor antagonists have shown limited efficacy as single agents.
Optimal application strategies for these targeted therapies remain undetermined.
Significant challenges exist in translating molecular insights into effective cancer treatments.

Conclusions:

Further research is needed to determine optimal treatment strategies for epidermal growth factor receptor antagonists.
Improved understanding of resistance mechanisms and combination therapies is crucial.
Addressing the limitations of current targeted therapies is essential for advancing cancer care.